You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Express Scripts
Dow
Boehringer Ingelheim
McKinsey
AstraZeneca
Moodys

Last Updated: February 21, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for IPI-549


Email this page to a colleague

See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug IPI-549?

IPI-549 is an investigational drug.

There have been 104 clinical trials for IPI-549. The most recent clinical trial was a Phase 3 trial, which was initiated on January 1st 2007.

The most common disease conditions in clinical trials are Lymphoma, Lymphoma, B-Cell, and Lymphoma, Large B-Cell, Diffuse. The leading clinical trial sponsors are Infinity Pharmaceuticals, Inc., Lymphoma Study Association, and Bristol-Myers Squibb.

Recent Clinical Trials for IPI-549
TitleSponsorPhase
Testing the Effects of Early Treatment With Venetoclax and Obinutuzumab Versus Delayed Treatment With Venetoclax and Obinutuzumab for Newly Diagnosed Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Do Not Have National Cancer Institute (NCI)Phase 3
A Study of NIVO Plus IPI and Guadecitabine or NIVO Plus IPI in Melanoma and NSCLC Resistant to Anti-PD1/PDL1Astex Pharmaceuticals, Inc.Phase 2
A Study of NIVO Plus IPI and Guadecitabine or NIVO Plus IPI in Melanoma and NSCLC Resistant to Anti-PD1/PDL1Bristol-Myers SquibbPhase 2

See all IPI-549 clinical trials

Clinical Trial Summary for IPI-549

Top disease conditions for IPI-549
Top clinical trial sponsors for IPI-549

See all IPI-549 clinical trials

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Medtronic
Dow
Colorcon
McKesson
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.